What Veran Medical Technologies does

Veran Medical Technologies operates a direct-to-consumer e-commerce platform that sells pharmaceutical-grade human growth hormone (HGH) and peptide products, with limited additional offerings in adjacent categories. The catalog spans branded somatropin products including Norditropin (Novo Nordisk), Genotropin and the long-acting Ngenla (Pfizer), Omnitrope (Sandoz), and ZPHC-manufactured HGH, alongside a peptide line covering Sermorelin, Ipamorelin, BPC-157, TB-500, Melanotan, and NAD+ compounds, with Semaglutide (a GLP-1 receptor agonist) added as a newer entry. The site presents itself as a no-prescription, direct-order storefront, publishing third-party laboratory test results and dosing content to support trust and organic search acquisition.

The business model is straightforward consumer e-commerce: the company prices products approximately 30% below the prevailing market average, offers bulk quantity tiers, and fulfills orders from US and Turkey warehouses with international shipping. Customers are individual adults seeking HGH, peptide therapy, bodybuilding, anti-aging, and weight-management products, ordering outside the traditional prescription-and-insurance pharmacy channel. The underlying technology stack appears to be a conventional content-managed e-commerce site (WordPress/WooCommerce-style), with no evidence of proprietary software, AI features, or platform infrastructure beyond standard storefront, payment, and content components.

Revenue mechanics are driven by per-unit catalog sales of relatively high-ticket injectable pharmaceuticals, with the supplier and channel structure serving as the primary differentiators rather than technology or brand depth. Given the no-presriction model, the business operates in a legally complex category in the United States, where HGH dispensing is restricted to physician prescription, and a meaningful share of demand is therefore sourced through cross-border shipping and gray-market channels. This regulatory posture, combined with single-vertical product concentration, is the single most important context for any investment view of the asset. Veran Medical Technologies operates a direct-to-consumer e-commerce platform that sells pharmaceutical-grade human growth hormone (HGH) and peptide products, with limited additional offerings in adjacent categories. The catalog spans branded somatropin products including Norditropin (Novo Nordisk), Genotropin and the long-acting Ngenla (Pfizer), Omnitrope (Sandoz), and ZPHC-manufactured HGH, alongside a peptide line covering Sermorelin, Ipamorelin, BPC-157, TB-500, Melanotan, and NAD+ compounds, with Semaglutide (a GLP-1 receptor agonist) added as a newer entry. The site presents itself as a no-prescription, direct-order storefront, publishing third-party laboratory test results and dosing content to support trust and organic search acquisition.

The business model is straightforward consumer e-commerce: the company prices products approximately 30% below the prevailing market average, offers bulk quantity tiers, and fulfills orders from US and Turkey warehouses with international shipping. Customers are individual adults seeking HGH, peptide therapy, bodybuilding, anti-aging, and weight-management products, ordering outside the traditional prescription-and-insurance pharmacy channel. The underlying technology stack appears to be a conventional content-managed e-commerce site (WordPress/WooCommerce-style), with no evidence of proprietary software, AI features, or platform infrastructure beyond standard storefront, payment, and content components.

Revenue mechanics are driven by per-unit catalog sales of relatively high-ticket injectable pharmaceuticals, with the supplier and channel structure serving as the primary differentiators rather than technology or brand depth. Given the no-prescription model, the business operates in a legally complex category in the United States, where HGH dispensing is restricted to physician prescription, and a meaningful share of demand is therefore sourced through cross-border shipping and gray-market channels. This regulatory posture, combined with single-vertical product concentration, is the single most important context for any investment view of the asset.

Name

Veran Medical Technologies

Legal name

Veran Medical Technologies

Website

http://www.veranmedical.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

Direct-to-consumer e-commerce retailer of pharmaceutical-grade human growth hormone (HGH), peptides, and GLP-1 products, sold at roughly 30% below market without prescription and shipped globally from US and Turkey warehouses to individual adult consumers. Direct-to-consumer e-commerce retailer of pharmaceutical-grade human growth hormone (HGH), peptides, and GLP-1 products, sold at roughly 30% below market without prescription and shipped globally from US and Turkey warehouses to individual adult consumers.

Ownership category

akta.pro rank

Headquarters

HQ city

St Louis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Digital Commerce or Content

Cost components

Supply Chain, Operations, Marketing or Sales, Technology or R&D, Personnel

Revenue model

1. HGH Product Sales: Direct e-commerce sales of Human Growth Hormone products including brands such as Genotropin, Zptropin, Somatropin, Omnitrope, Ngenla, and Spectros. Products sold as one-time purchases with varying dosages and formulations.
2. Peptide Product Sales: Sales of peptide products including BPC 157, GHRP-2, GHRP-6, Ipamorelin, TB-500, NAD+, IGF-1 LR3, and combination mixes. Sold through same e-commerce platform with free shipping thresholds.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Veran Medical Technologies operates a direct-to-consumer e-commerce platform that sells pharmaceutical-grade Human Growth Hormone (HGH) and peptide-based therapy products to individual buyers. The company sources from manufacturers including Pfizer (Genotropin), Sandoz (Omnitrope), ZPHC, Spectros, ZPtrop, Ngenla, and Canada Peptides, fulfilling orders from warehouses in the USA and Turkey. Each product is third-party lab-tested after cold-chain exposure and ships with manufacturer authentication codes.

Product overview

Veran Medical Technologies operates an e-commerce platform selling pharmaceutical-grade Human Growth Hormone (HGH) products and peptide-based therapies. The product portfolio consists of two main categories: HGH Products (including Genotropin by Pfizer, Ngenla long-acting HGH, Omnitrope, and various Chinese-manufactured brands like Zptropin, Spectros, and Somatropin) and Peptide Products (including BPC 157, GHRP-2, GHRP-6, IGF-1 LR3, Ipamorelin, CJC-1295 combinations, NAD+, Semaglutide, TB-500, and pre-mixed recovery stacks). The company ships from warehouses in the USA and Turkey, offering both domestic and international delivery options. Products are sourced from reputable manufacturers including Pfizer, Sandoz, Spectrum Pharma, ZPHC, and Canada Peptides, with lab test results published to verify authenticity and purity.

Differentiator

Problem solved

Functional benefit

Products and services

• Genotropin 36 IU HGH Pen
• Ngenla 180 IU HGH Pen
• Ngenla 72 IU HGH Pen
• Omnitrope 45 IU HGH Pen
• Spectros 280 IU HGH Pen
• Zptropin 200 IU HGH
• Somatropin 191aa 150 IU
• Spectros 140 IU HGH
• Zptrop 150 AQ Premixed HGH Pen
• ZPtrop AQ 36 IU Pen
• Zptropin 160 IU HGH
• ZPtropin 320 IU HGH
• BPC 157 Peptide (5 mg)
• GHRP-2 Peptide (5 mg)
• GHRP-6 Peptide (5 mg)
• HP-HCG (5,000 IU)
• IGF-1 LR3 (1 mg)
• Ipamorelin (5 mg)
• Mega Mass Mix Peptide Blend (5 mg)
• NAD+ Peptide (5 mg)
• Semaglutide 2 mg Peptide
• Semaglutide 5 mg Peptide
• TB-500 Peptide (5 mg)
• Ultra Rehab Mix Peptide Blend (5 mg)
• Wellness Mix Peptide Blend (5 mg)

Quantifiable outcome

• Zptropin purity: 95.156% (tested at 28.38 IU content)
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Five partnerships are on record, tiered core and minor.

• ZPHC (Zhangjiagang Pharmaceutical)coreOthersPrimary Chinese manufacturer supplying Zptropin, Zptrop AQ, and various peptide products. Products include verification codes on ZPHC.com for authenticity checking. Long-standing supplier relationship.
• Spectrum PharmacoreOthersManufacturer of Spectros brand HGH products. Founded in 2009, known for producing high-purity HGH verified through official website. Supplies 140 IU and 280 IU Spectros kits.
• Canada PeptidescoreOthersCanadian manufacturer producing Somatropin 191aa products. Known for high-quality manufacturing with 97%+ purity targets. Verification available through check-canadapeptides.org.
• Pfizer (Genotropin, Ngenla)minorOthersWestern pharmaceutical manufacturer supplying Genotropin and Ngenla (somatrogon) products. Genotropin shipped from Turkish pharmacy warehouse; Ngenla is long-acting weekly HGH formulation by Pfizer.
• Sandoz (Omnitrope)minorOthersSandoz subsidiary of Novartis manufactures Omnitrope, a biosimilar HGH product. Distributed through Turkish pharmacy warehouse with free shipping on orders of 300+ IU.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Brainlab: Direct peer offering image-guided surgery platforms across multiple specialties, including cranial, spine, and trauma. Closely comparable business model of software-and-instrumentation navigation systems sold to hospitals and academic medical centers.
• Medtronic: Direct competitor in image-guided navigation, with the superDimension electromagnetic navigation system for lung biopsy and StealthStation for cranial/spine procedures. Closest direct comparable in procedural navigation and hospital-channel sales motion.
• Intuitive Surgical: Direct competitor in image-guided lung biopsy via the Ion robotic-assisted platform, targeting the same pulmonology procedure category with a shape-sensing robotic catheter. Comparable clinical use case and target hospital customer.
• Body Vision Medical: Emerging direct competitor in lung navigation, focused specifically on bronchoscopic guidance for pulmonary lesion diagnosis. Closely comparable clinical use case (peripheral lung nodule biopsy) and target customer (interventional pulmonologists).

Broad incumbents

• GE HealthCare: Broad incumbent in medical imaging equipment whose CT and image-guidance modalities are commonly paired with surgical navigation platforms. Comparable at the imaging infrastructure layer that enables image-guided procedures.
• Philips: Broad incumbent in image-guided therapy and interventional imaging, including Azurion and EPIQ platforms used in image-guided interventions. Comparable at the hybrid OR / interventional imaging layer.
• Siemens Healthineers: Broad incumbent providing the underlying imaging hardware (CT, fluoroscopy, C-arm) that image-guided navigation systems integrate with. Comparable at the imaging-and-navigation intersection, though positioned upstream as the imaging modality provider.
• Stryker: Broad incumbent with surgical navigation systems (incl. SpineMask and cranial navigation) embedded in a much larger orthopedics and surgical instruments portfolio. Comparable navigation technology, but distributed via Stryker's larger hospital sales force and bundled capital agreements.
• Johnson & Johnson: Broad medical device incumbent with overlapping capabilities across interventional oncology and biosurgery. Comparable from both a strategic-acquirer perspective and a portfolio-overlap standpoint in image-guided intervention.
• Olympus Corporation: Broad incumbent in endoscopy and pulmonology visualization with adjacent positioning to bronchoscopic navigation. Comparable at the procedural-endoscopy intersection, particularly in lung biopsy workflows.

Market position

Strengths4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/veranmedical
• Facebookfacebook.com/2337123
• LinkedInlinkedin.com/company/veran-medical-technologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds19 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Veran Medical Technologies